Decitabine-Induced Posterior Reversible Encephalopathy Syndrome in a Patient with Myelodysplastic Syndrome
Authors:
- Kyung Wook KangKKKyung Wook Kang
- You-Ri KangYKYou-Ri Kang
- Seo-Yeon AhnSASeo-Yeon Ahn
- Myeong-Kyu KimMKMyeong-Kyu Kim
Open Access
- 30 September 2022
- journal article
- Published by Korean Clinical Epilepsy Research Society in Epilia: Epilepsy and Community
- Vol. 4 (2) , 68-72
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Mechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the EpicenterFrontiers in Oncology, 2021
- Decitabine-induced kidney thrombotic microangiopathy with glomerular crescents formation and tubular necrosisMedicine, 2020
- Controversy of posterior reversible encephalopathy syndrome: what have we learnt in the last 20 years?Journal of Neurology, Neurosurgery & Psychiatry, 2017
- Chemotherapy-associated Posterior Reversible Encephalopathy SyndromeThe Neurologist, 2016
- Posterior reversible encephalopathy syndrome—Insight into pathogenesis, clinical variants and treatment approachesAutoimmunity Reviews, 2015
- Suspicious Neuroimaging Pattern of Thrombotic MicroangiopathyAmerican Journal of Neuroradiology, 2011
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006
- Changes in DNA Methylation in Neoplasia: Pathophysiology and Therapeutic ImplicationsAnnals of Internal Medicine, 2001
- A Reversible Posterior Leukoencephalopathy SyndromeNew England Journal of Medicine, 1996